FOR US RESIDENTS ONLY
NOW APPROVED For the treatment of Dystrophic Epidermolysis Bullosa (DEB) in patients 6 months and older

VYJUVEK Voices

Real Patients. Real Experiences. Real Support.

If you are considering starting therapy with VYJUVEK

Why not speak to someone who already has it.

VYJUVEK Voices connects you with an individual who has real experience using VYJUVEK. Whether you’re preparing for your first application or just want to hear how someone else made the decision and got started, this one-on-one conversation gives you the chance to ask questions and receive helpful guidance.

Through this connection, you will:

  • Attain practical advice on wound healing, application, and daily life with VYJUVEK
  • Hear what to expect on your treatment journey from someone with firsthand experience.
  • Gain confidence and reassurance from another who understands what it’s like to live with DEB.

Vanessa

“As a 38-year-old who has been dealing with EB since birth, I’m so grateful for VYJUVEK because we finally have a treatment for this devastating disease. VYJUVEK not only gives me hope, but it gives parents and future generations of patients an option that we never had”

— Vanessa, VYJUVEK Ambassador

Sign Up












INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

  • Please see Important Safety Information above and click here for full Prescribing Information.
IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

  • Please see Important Safety Information above and click here for full Prescribing Information.